Aeterna Zentaris logo
Aeterna Zentaris AEZS
report update icon

Quarterly report 2025-Q4
added 05-08-2026

Aeterna Zentaris Balance Sheet 2025-2011 | AEZS

Brief overview of Aeterna Zentaris's balance sheet strength

The review uses the five latest available annual reports between 2021 and 2025.

Assets finished at $21.4 million versus $80.1 million initially, losing -73.2%. The balance sheet contracted.

Liabilities expanded faster than the asset base, -35.1% versus -73.2%. Debt-service capacity deserves attention.

Cash exceeds interest-bearing debt, producing net debt of -$5.2 million. The balance sheet therefore carries a net cash position.

Cash represents 34.1% of assets versus 81.5% initially, showing how the immediate liquidity reserve changed.

The accumulated result is -$20.5 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

What the balance sheet shows

Aeterna Zentaris's balance sheet presents a mixed picture: strengths coexist with a limited cushion. Future capital and debt trends are particularly important.

Annual Balance Sheet Aeterna Zentaris

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-5.16 M -14.1 M -4.98 M -10 M -65.1 M - - - - -22 M -34.9 M -34.9 M -43.2 M -39.5 M -46.8 M

Long Term Debt

1.93 M 2.04 M 1.4 M 65 K 31 K - - - - - - - - - 29 K

Long Term Debt Current

215 K 271 K 299 K 114 K 130 K 135 K 648 K - - - - - - - -

Total Non Current Liabilities

14 M 14.7 M 1.4 M 13.2 M - 19.1 M 16.8 M 17.5 M 19.2 M 21.2 M - 25.4 M 34.9 M 58.7 M 62 M

Total Liabilities

17.6 M 21.9 M 2.71 M 4.02 M 27.1 M 23.8 M 22.4 M 23.1 M 25 M 25.4 M 33 M 33 M 42.1 M 74.4 M 79.9 M

Deferred Revenue

- - - - - 2.19 M 991 K 74 K 486 K 426 K 270 K 270 K - 5.24 M 5.31 M

Retained Earnings

-20.5 M -12.1 M 4.36 M -352 M -335 M -323 M -317 M -310 M -314 M -298 M - -222 M -204 M -213 M -189 M

Total Assets

21.4 M 35.1 M 23.7 M 27.8 M 80.1 M 37 M 20 M 25 M 22.2 M 31.7 M 47.4 M 47.4 M 59.2 M 67.7 M 75.4 M

Cash and Cash Equivalents

7.31 M 16.4 M 6.68 M 10.2 M 65.3 M 24.3 M 7.84 M 14.5 M 7.78 M 22 M 41.4 M - - - -

Book Value

3.84 M 13.2 M 21 M 23.8 M 53 M 13.2 M -2.46 M 1.91 M -2.78 M 6.21 M 14.5 M 14.5 M 17.1 M -6.7 M -4.55 M

All numbers in USD currency

Quarterly Balance Sheet Aeterna Zentaris

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

1.93 M 1.96 M 2.05 M 1.97 M 2.04 M 1.21 M 1.28 M 80 K 1.4 M 70 K 85 K 76 K - - - 22 K 31 K 65 K 12 K 15 K 49 K 76 K 103 K 144 K 255 K 408 K 570 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

14 M 14.8 M 14.9 M 13.9 M 14.7 M 15.6 M 13.9 M 13.6 M 1.4 M 12 M 13.3 M 13.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

17.6 M 18.8 M 20.5 M 21 M 21.9 M 23.8 M 23.8 M 18.8 M 2.71 M 16.2 M 17.4 M 20.1 M - - - 23.2 M 27.1 M 22.1 M 23 M 22.8 M 23.8 M 17.1 M 16.7 M 18 M 22.4 M 23.7 M 23.8 M - 23.1 M - - - 25 M - - - 25.4 M - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-20.5 M -19 M -17.2 M -14.7 M -12.1 M -5.16 M 1.53 M -375 M 4.36 M -362 M -359 M -357 M - - - -335 M -335 M -328 M -326 M -323 M -323 M -321 M -320 M -315 M -317 M -317 M -316 M - -310 M - - - -314 M - - - -298 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

21.4 M 23.9 M 27.6 M 31.1 M 35.1 M 43.8 M 50 M 31.8 M 23.7 M 42.5 M 46.5 M 51.3 M - - - 76.3 M 80.1 M 82 M 84.4 M 87 M 37 M 32.3 M 17.7 M 19.6 M 20 M 21.5 M 20.8 M - 25 M - - - 22.2 M - - - 31.7 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

7.31 M 8.52 M 9.33 M 13.8 M 16.4 M 20 M 27.8 M 29.5 M 6.68 M 38.8 M 42.2 M 46.6 M - - - 63.6 M 65.3 M 68 M 69.9 M 73.4 M 24.3 M 21.7 M 6.74 M 9.18 M 7.84 M 10.9 M 9.68 M 11.4 M 14.5 M 16.8 M 19.9 M 24.5 M 7.78 M - - - 22 M - - - 41.4 M - - - 34.9 M - - - - - - - - - - - - - - -

Book Value

3.84 M 5.08 M 7.1 M 10.1 M 13.2 M 20 M 26.2 M 13 M 21 M 26.3 M 29.1 M 31.2 M - - - 53.2 M 53 M 59.9 M 61.3 M 64.2 M 13.2 M 15.1 M 931 K 1.69 M -2.46 M -2.19 M -3.03 M - 1.91 M - - - -2.78 M - - - 6.21 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Aeterna Zentaris, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.8 0.94 % $ 1.63 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA